Merck starts Phase 3 ENHANCE-3 trial of Ohtuvayre to prevent COPD exacerbations
Merck, known as MSD outside of the United States and Canada, announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the… read more.
